News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NovoCure Limited - Ordinary Shares
(NQ:
NVCR
)
17.77
-0.05 (-0.28%)
Streaming Delayed Price
Updated: 10:27 AM EDT, Aug 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NovoCure Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Novocure Reports Second Quarter 2026 Financial Results
July 23, 2026
From
Novocure
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
July 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
July 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Novocure to Report Second Quarter 2026 Financial Results
July 01, 2026
From
Novocure
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
June 30, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
June 30, 2026
From
Novocure
Via
Business Wire
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
June 20, 2026
From
The Schall Law Firm
Via
Business Wire
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
June 18, 2026
From
Novocure
Via
Business Wire
Novocure Reports First Quarter 2026 Financial Results
April 30, 2026
From
Novocure
Via
Business Wire
Novocure to Report First Quarter 2026 Financial Results
April 01, 2026
From
Novocure
Via
Business Wire
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
March 26, 2026
From
Novocure
Via
Business Wire
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
March 02, 2026
From
Novocure
Via
Business Wire
Novocure to Participate in 2026 Leerink Global Healthcare Conference
February 27, 2026
From
Novocure
Via
Business Wire
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
February 26, 2026
From
Novocure
Via
Business Wire
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
February 24, 2026
From
Novocure
Via
Business Wire
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
February 11, 2026
From
Novocure
Via
Business Wire
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
January 12, 2026
From
Novocure
Via
Business Wire
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
December 22, 2025
From
Novocure
Via
Business Wire
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
December 01, 2025
From
Novocure
Via
Business Wire
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
November 26, 2025
From
Novocure
Via
Business Wire
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
November 12, 2025
From
Novocure
Via
Business Wire
Novocure Reports Third Quarter 2025 Financial Results
October 30, 2025
From
Novocure
Via
Business Wire
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
October 15, 2025
From
Novocure
Via
Business Wire
Novocure to Report Third Quarter 2025 Financial Results
October 01, 2025
From
Novocure
Via
Business Wire
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
September 29, 2025
From
Novocure
Via
Business Wire
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
September 15, 2025
From
Novocure
Via
Business Wire
Novocure Announces Upcoming Investor Events
August 28, 2025
From
Novocure
Via
Business Wire
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
August 25, 2025
From
Novocure
Via
Business Wire
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
August 20, 2025
From
Novocure
Via
Business Wire
Novocure Reports Second Quarter 2025 Financial Results
July 24, 2025
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
